



Attorney's Docket No.: 12774-002001

1619  
#10a  
Da  
2/6/02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Hsu et al.  
Serial No. : 09/778,672  
Filed : February 7, 2001  
Title : LIVE VACCINES FOR ALLERGY TREATMENT

Art Unit : 1619  
Examiner : Unknown

Commissioner for Patents  
Washington, D.C. 20231

RECEIVED  
JAN 22 2002  
TECH CENTER 1600/2900

PRELIMINARY AMENDMENT

Prior to examination, please amend the application as follows. In the specification, replace the paragraph beginning at page 1, line 13 with the following rewritten paragraph:

-- The invention is based on the discovery that recombinant lactic acid bacteria expressing a protein allergen can induce immunological tolerance against the allergen in animal models. In addition, this tolerance was sufficient to reduce symptoms associated with exposure to the allergen, such as airway hyperreactivity and inflammation. Given the high level of unpredictability in the art of live recombinant vaccines, this successful result was unexpected. --

01/22/2002 FFANAEIA 00000002 09778672

01 FC:202

42.00 OP

CERTIFICATE OF MAILING BY FIRST CLASS MAIL

I hereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, Washington, D.C. 20231.

December 5, 2001

Date of Deposit

Marie A. Colokathis  
Signature

Marie A. Colokathis

Typed or Printed Name of Person Signing Certificate